RedHill Biopharma Ltd. announced the mutual decision with Cosmo Technologies Ltd. to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea. The License Agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024. Per the terms of the License Agreement, RedHill will immediately cease any Aemcolo commercialization of Aemcolo upon termination of the License Agreement, at which point all rights previously ascribed in the License Agreement to RedHill will revert to Cosmo.